Biotech

Corbus Pharmaceuticals to Present Additional Data on the Effects of Resunab(TM) in the Treatment of Pulmonary Infection and Inflammation in Pre-Clinical Models of Cystic Fibrosis

NORWOOD, MA: Data to Be Presented at the North American Cystic Fibrosis Conference October 8-10, 2015; Resunab Demonstrated Improvement in Lung Inflammation and Infection in Cystic Fibrosis Pre-Clinical Model ...

Sernova Announces Listing on OTCQB Exchange

LONDON, ONTARIO: LONDON, ONTARIO -- (Marketwired) -- 09/21/15 -- Sernova Corp. (TSX VENTURE: SVA)(FRANKFURT: PSH)(OTCQB: SEOVF), a leading clinical stage, regenerative medicine company developing biologically compat ...

Theratechnologies to Announce Financial Results for the Third Quarter of 2015

MONTREAL, QUEBEC: MONTREAL, QUEBEC -- (Marketwired) -- 09/21/15 -- Theratechnologies Inc. (TSX: TH) (Theratechnologies) announced today that it will issue its financial results for the third quarter ended August 31, ...

Data From New Studies Confirm In Vitro Potency of VIBATIV(R) (Telavancin) Against Gram-Positive Bacteria, Including MRSA

DUBLIN, IRELAND: In Vitro Potency Results Presented at 2015 ICAAC Demonstrate Advantage for VIBATIV Against Difficult-to-Treat Infections as Compared to Vancomycin, Daptomycin and Linezolid ...

Corbus Pharmaceuticals Commences Patient Enrollment in Phase 2 Clinical Study of Resunab(TM) for the Treatment of Cystic Fibrosis

NORWOOD, MA: Study in Cystic Fibrosis Is the Third Phase 2 Clinical Trial Underway With Resunab for Treatment of Rare, Serious Inflammatory and Fibrotic Diseases ...

Arch Biopartners: AB569 Successfully Completes Pre-Clinical Validation Studies

TORONTO, CANADA: TORONTO, CANADA -- (Marketwired) -- 09/17/15 -- Arch Biopartners Inc (Arch) or (the Company) (TSX VENTURE: ACH)(OTCBB: FOIFF) announced AB569, the Company's drug candidate for treating pulmonar ...

Calyx's Subsidiary Cannigistics Announces Platform Licensing Agreement

VANCOUVER, BRITISH COLUMBIA: VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 09/17/15 -- Calyx Bio-Ventures Inc. (TSX VENTURE: CYX) ("Calyx" or "the Company") is pleased to announce that its wholly-owned sub ...

Sermonix Pharmaceuticals to Present Three Lasofoxifene Papers and One Poster at the North American Menopause Society Meeting

COLUMBUS, OH: Company to Share Results From Studies of Investigational Drug, Lasofoxifene ...

Medivation Effects a Stock Dividend on Its Common Stock

SAN FRANCISCO, CA: SAN FRANCISCO, CA -- (Marketwired) -- 09/16/15 -- Medivation, Inc. (NASDAQ: MDVN) today announced that it has effected a stock dividend on its common stock, in which each outstanding share of common ...

Flamel Technologies to Present at Ladenburg Thalmann 2015 Healthcare Conference

LYON, FRANCE: LYON, FRANCE -- (Marketwired) -- 09/15/15 -- Flamel Technologies (NASDAQ: FLML) today announced that the Company will be presenting at the Ladenburg Thalmann 2015 Healthcare Conference to be held at ...